Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004171
Status:
COMPLETED
Last Update Posted:
2012-06-12
First Post:
1999-12-10
Brief Title:
Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkins Disease or Non-Hodgkins Lymphoma
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Autologous Blood Stem Cell Transplantation in Patients With Hodgkins Disease and Non-Hodgkins Lymphoma Who Have Had Prior Radiation Therapy
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells
PURPOSE Phase II trial to study the effectiveness of chemotherapy followed by peripheral stem cell transplantation in treating patients who have Hodgkins disease or non-Hodgkins lymphoma
PURPOSE Phase II trial to study the effectiveness of chemotherapy followed by peripheral stem cell transplantation in treating patients who have Hodgkins disease or non-Hodgkins lymphoma
Detailed Description:
OBJECTIVES I Determine the toxicity and response to intensive chemotherapy followed by autologous peripheral blood stem cell transplantation in patients with Hodgkins disease or non-Hodgkins lymphoma who have received prior chemotherapy andor radiotherapy
OUTLINE Patients receive oral busulfan every 6 hours on days -9 to -6 and cyclophosphamide IV over 2 hours on days -5 to -2 Autologous peripheral blood stem cells are reinfused on day 0 Patients are followed monthly for 1 year
PROJECTED ACCRUAL Not specified
OUTLINE Patients receive oral busulfan every 6 hours on days -9 to -6 and cyclophosphamide IV over 2 hours on days -5 to -2 Autologous peripheral blood stem cells are reinfused on day 0 Patients are followed monthly for 1 year
PROJECTED ACCRUAL Not specified
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NU-87H6T | None | None | None |
| NCI-G99-1638 | None | None | None |